

Adalimumab

Section	Indications
Immunomodulators for non-malignant disease Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL	<ul style="list-style-type: none"> Axial spondyloarthritis Juvenile idiopathic arthritis Crohn disease site Rheumatoid arthritis

Azathioprine

Section	Indications
Immunomodulators for non-malignant disease Parenteral > General injections > IV: 100 mg in vial powder for injection (as sodium salt) Oral > Solid: 50 mg	<ul style="list-style-type: none"> Failure or rejection of transplanted organs or tissues Relapsing-remitting multiple sclerosis

Certolizumab pegol

Section	Indications
Immunomodulators for non-malignant disease	Therapeutic equivalent to adalimumab for <ul style="list-style-type: none"> Axial spondyloarthritis Therapeutic equivalent to adalimumab for <ul style="list-style-type: none"> Juvenile idiopathic arthritis Therapeutic equivalent to adalimumab for <ul style="list-style-type: none"> Crohn disease site Therapeutic equivalent to adalimumab for <ul style="list-style-type: none"> Rheumatoid arthritis

Ciclosporin

Section	Indications
Immunomodulators for non-malignant disease Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection Oral > Solid: 25 mg	<ul style="list-style-type: none"> Failure or rejection of transplanted organs or tissues

Etanercept

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for

Axial spondyloarthritis

Therapeutic equivalent to [adalimumab](#) for

Juvenile idiopathic arthritis

Therapeutic equivalent to [adalimumab](#) for

Crohn disease site

Therapeutic equivalent to [adalimumab](#) for

Rheumatoid arthritis

Fingolimod

Section

Immunomodulators for non-malignant disease
Oral > Solid: 0.25 mg; 0.5 mg

Indications

Relapsing-remitting multiple sclerosis

Glatiramer acetate

Section

Immunomodulators for non-malignant disease
Parenteral > General injections > SC: 20 mg per mL; 40 mg per mL

Indications

Relapsing-remitting multiple sclerosis

Golimumab

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for

Axial spondyloarthritis

Therapeutic equivalent to [adalimumab](#) for

Juvenile idiopathic arthritis

Therapeutic equivalent to [adalimumab](#) for

Crohn disease site

Therapeutic equivalent to [adalimumab](#) for

Rheumatoid arthritis

Infliximab

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for

Axial spondyloarthritis

Therapeutic equivalent to [adalimumab](#) for

Juvenile idiopathic arthritis

Therapeutic equivalent to [adalimumab](#) for

Crohn disease site

Therapeutic equivalent to [adalimumab](#) for

Rheumatoid arthritis

Ocrelizumab

Section

Immunomodulators for non-malignant disease

Parenteral > General injections > IV: 30 mg per mL in 10 mL vial

Indications

Relapsing-remitting multiple sclerosis